# Sirolimus for Autoimmune Disease of Blood Cells

> **NCT00392951** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Hospital of Philadelphia** · enrollment: 30 (actual)

## Conditions studied

- Autoimmune Pancytopenia
- Autoimmune Lymphoproliferative Syndrome (ALPS)
- Evans Syndrome
- Idiopathic Thrombocytopenic Purpura
- Anemia, Hemolytic, Autoimmune
- Autoimmune Neutropenia
- Lupus Erythematosus, Systemic
- Inflammatory Bowel Disease
- Rheumatoid Arthritis

## Interventions

- **DRUG:** sirolimus

## Key facts

- **NCT ID:** NCT00392951
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392951, "Sirolimus for Autoimmune Disease of Blood Cells". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00392951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*